If You Invested in Rubius Therapeutics (RUBY)
Looking for the current price? See the RUBY quote & overviewWhat $1,000 or $10,000 in RUBY Would Be Worth Now
Real historical value by amount invested and how long ago| If you invested | 1 year ago | 5 years ago | 10 years ago | Since Jul 18, 2018 |
|---|---|---|---|---|
| $1,000 | — | $4 -100% | — | $2 -100% |
| $10,000 | — | $40 -100% | — | $24 -100% |
Based on real historical closing prices adjusted for stock splits, without dividends, through 2023-12-29. Figures with dividends reinvest each cash dividend at the previous close less the dividend, before taxes. Past performance does not guarantee future results.
Custom Calculation
Choose your own date and amount for RUBY$1,000 Investment Over Time
RUBY vs S&P 500Year-by-Year Returns
RUBY annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2018 | $24.25 | $16.08 | -33.7% | -33.7% |
| 2019 | $16.08 | $9.50 | -40.9% | -60.8% |
| 2020 | $9.50 | $7.59 | -20.1% | -68.7% |
| 2021 | $7.59 | $9.68 | +27.5% | -60.1% |
| 2022 | $9.68 | $0.1750 | -98.2% | -99.3% |
| 2023 | $0.1750 | $0.0570 | -67.4% | -99.8% |
About Rubius Therapeutics
OTC
Frequently Asked Questions
Rubius Therapeutics investment returns
How much would $1,000 invested in Rubius Therapeutics be worth today?
If you invested $1,000 in Rubius Therapeutics (RUBY) 5 years ago on 2021-10-29, your investment would be worth $4 as of 2023-12-29, a -99.6% price return without dividends, growing at a compounded rate of -92.2% per year (CAGR).
Has Rubius Therapeutics outperformed the S&P 500?
Comparison data requires at least 10 years of trading history. Use the calculator above to compare RUBY performance over available time periods.
What is Rubius Therapeutics's average annual return?
The compound annual growth rate (CAGR) of RUBY’s share price over the past 5 years is -92.2%, without dividends. Individual years vary a great deal, and RUBY’s best recent full year was 2021 (+27.5%) while the worst was 2022 (-98.2%).
For informational and educational purposes only, not investment advice.
